EN | UA
EN | UA

Help Support

Back

Nimotuzumab may modulate COVID-19 linked hyperinflammation and prevent fibrosis, study reveals!

Nimotuzumab may modulate COVID-19 linked hyperinflammation and prevent fibrosis, study reveals! Nimotuzumab may modulate COVID-19 linked hyperinflammation and prevent fibrosis, study reveals!
Nimotuzumab may modulate COVID-19 linked hyperinflammation and prevent fibrosis, study reveals! Nimotuzumab may modulate COVID-19 linked hyperinflammation and prevent fibrosis, study reveals!

What's new?

Anti-EGFR antibodies like nimotuzumab can contribute to the recovery of coronavirus-infected people without any long-term adverse consequences.

A case series published in Immunotherapy indicated that nimotuzumab may be associated with modulation of hyperinflammation and prevention of fibrosis in COVID-19 patients. Investigators aimed to determine the preliminary safety and effect of nimotuzumab (a humanized anti-epidermal growth factor receptor [EGFR] antibody) in individuals with real time-polymerase chain reaction confirmed coronavirus infection.

Nimotuzumab was utilized to manage 3 people suffering from moderate or severe SARS-CoV-2 infection. The antibody was given in combination with other drugs incorporated in the national COVID-19 protocol.

Nimotuzumab displayed a good safety profile. Moreover, nimotuzumab infusion decreased the concentration of interleukin-6, a vital inflammatory marker. Following  nimotuzumab therapy,  a drop in the levels of other inflammatory markers (ferritin, lactate dehydrogenase, c-reactive protein, and neutrophil-lymphocyte ratio) was also noted.

After nimotuzumab administration, remarkable improvements in clinical symptoms were noted. The computed tomography scans at discharge revealed major resolution of the lung lesions without any signs of fibrosis. Thus, rapid clinical and radiological improvements were noted in nimotuzumab-treated patients.

Source:

Immunotherapy

Article:

Nimotuzumab for COVID-19: case series

Authors:

Anselmo A Abdo Cuza et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: